Leaders in the Innovation Economy Reach out to Senate Leadership on Medical Device Tax Repeal

Leaders from over 800 organiztions and companies focused on grwoing our econony and supporting medical device innovation sent a letter to Senate leadership this today calling for repeal of the medical device tax.

The letter included three important reasons to suport repeal:

    • The tax will stifle innovation and cost thousands of high-paying jobs. It will increase the effective tax rate for many medical technology companies, thereby reducing financial resources that should be used for R&D, clinical trials and investments in manufacturing. The impact will be especially hard on smaller companies whose innovations are not immediately profitable.
    • The tax will increase health care costs as confirmed by a report issued in April 2010 by the Office of the Actuary at the Centers for Medicare and Medicaid Services (CMS). In some cases, the 2.3% tax will be passed on to consumers, leading to higher health care costs.
    • The tax will not be offset by increased demand for medical devices. In fact, it is important to note that there is no evidence suggesting a device industry “windfall” from healthcare reform. Unlike other industries that may benefit from expanded coverage, the majority of device-intensive medical procedures are performed on patients that are older and already have private insurance or Medicare coverage. Where states have dramatically extended health coverage, such as in Massachusetts where they added 400,000 new covered lives, there is no evidence of a device “windfall.”

At a time when the federal government is working to promote investment in U.S. industries of the future, it is inconsistent that a tax of this magnitude would be considered on the medical device industry. We must do all we can to encourage and promote research, development, investment and innovation. Instead, increased taxes, such as this one on the medical device industry, coupled with the increased regulatory uncertainty the industry also faces, will lead to further job losses, hinder the development of breakthrough treatments and delay patient access to medical technology.

To read the  full  text and view the list of signatories, please cliche here:  2012-11-13 Medical Device Tax letter to Senate Leadership

UA Cancer Center awarded $9.6 million for prevention agent studies

TUCSON, Ariz. – The University of Arizona Early Phase Chemoprevention Consortium led by UA Cancer Center researchers Sherry Chow, PhD, and David Alberts, MD, has been awarded funding by the National Cancer Institute to conduct early-phase clinical trials to evaluate the safety, clinical activity, and biological effects of novel cancer preventive agents. This five-year award will total up to $9.6 million.Continue reading